The blood collection tubes for liquid biopsy market are expanding rapidly as liquid biopsy technologies gain prominence in precision medicine, oncology diagnostics, and translational research. Liquid biopsy enables the detection and analysis of biomarkers such as circulating tumor DNA (ctDNA), cell‑free DNA (cfDNA), circulating tumor cells (CTCs), and cfRNA from blood, offering a noninvasive alternative to tissue biopsy. Specialized blood collection tubes are critical to this workflow, as they stabilize fragile biomarkers at the point of collection and preserve sample integrity throughout transport and processing.
The blood collection tubes for liquid biopsy market size is projected to reach US$ 428.66 million by 2031, up from US$ 110.13 million in 2023. The market is expected to register a robust CAGR of 18.5% during 2023–2031, underscoring strong adoption across clinical diagnostics, research laboratories, and pharmaceutical development.
Download Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00019989
Key Market Drivers Accelerating Growth
Rising Global Cancer Burden
The increasing prevalence of cancer worldwide remains the most powerful driver of market growth. Liquid biopsy has become an essential tool for early detection, prognosis, therapy selection, and treatment monitoring. As cancer cases continue to rise, so does the volume of liquid biopsy testing—directly fueling demand for advanced blood collection tubes capable of preserving nucleic acids and cells without degradation.
Growing Preference for Noninvasive Diagnostics
Healthcare providers and patients increasingly favor noninvasive diagnostic solutions that reduce procedural risk and improve patient comfort. Liquid biopsy enables frequent and repeat sampling, which is often impractical with tissue biopsies. This advantage leads to higher testing frequency and, consequently, greater consumption of liquid biopsy‑specific blood collection tubes designed to minimize cellular lysis and genomic contamination.
Advancements in Molecular and Genomic Technologies
Breakthroughs in next‑generation sequencing (NGS), digital PCR, and biomarker analytics have heightened the need for standardized pre‑analytical workflows. Liquid biopsy assays are highly sensitive, making sample quality paramount. Advanced blood collection tubes with proprietary stabilization chemistries are increasingly required to ensure reproducibility, accuracy, and compatibility with automated molecular platforms.
Expansion of Precision Medicine and Companion Diagnostics
Precision medicine initiatives are scaling globally, particularly within oncology. Pharmaceutical companies are leveraging liquid biopsy in clinical trials for patient stratification, minimal residual disease monitoring, and real‑time treatment response assessment. This growing reliance on liquid biopsy throughout drug development is driving strong demand for validated blood collection tubes that meet clinical and regulatory requirements.
Increasing R&D in Biomarker Discovery
Biotechnology firms, diagnostic developers, and academic institutions are investing heavily in biomarker discovery for early disease detection and monitoring. High‑quality biospecimens are foundational to successful biomarker validation, which elevates the importance of specialized blood collection tubes optimized for preserving cfDNA, cfRNA, and CTCs over extended timeframes.
Growth in Diagnostic Infrastructure in Emerging Economies
Emerging markets are strengthening diagnostic capabilities through healthcare investments and laboratory expansion. Rising awareness of cancer screening, improving access to molecular diagnostics, and government‑backed precision medicine programs—particularly across Asia‑Pacific and parts of Latin America—are expanding liquid biopsy adoption and supporting long‑term market growth.
Market Segmentation Insights
By product type, cfDNA and ccfDNA blood collection tubes command a significant share due to their widespread use in oncology diagnostics. cfRNA and CTC tubes are gaining traction as research expands into transcriptomic and cellular biomarkers.
From an application standpoint, in‑vitro diagnostics (IVD) dominates the market, followed by research use. Genetic diagnostic laboratories and research institutions represent key end users, reflecting growing molecular testing volumes and translational research activity.
Regional Landscape
North America leads the market, supported by advanced healthcare infrastructure, high adoption of liquid biopsy, and robust oncology research. Europe continues to grow steadily, driven by strong regulatory frameworks and increasing molecular diagnostics integration.
The Asia‑Pacific region is expected to register the fastest growth through 2031 due to rising cancer incidence, expanding laboratory networks, and increased investment in precision medicine and genomic testing.
Get Full Copy @ https://www.theinsightpartners.com/buy/TIPRE00019989
Competitive Landscape and Key Players
Major players operating in the blood collection tubes for liquid biopsy market include:
- Roche
- Streck, Inc.
- PreAnalytiX GmbH
- Norgen Biotek Corp.
- Biocept, Inc.
- Illumina, Inc.
These companies focus on innovation in stabilization chemistry, regulatory‑compliant product development, and strategic collaborations with assay and platform providers to strengthen their competitive positions.
Related Reports @
Liquid Biopsy Market Analysis, Size, and Share by 2031
About Us –
The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.
Contact Us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : Korean German Japanese French Chinese Italian Spanish
